collection
MENU ▼
Read by QxMD icon Read
search

Radioterapia Ca Próstata

shared collection
61 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28126300/effect-of-long-term-hormonal-therapy-vs-short-term-hormonal-therapy-a-secondary-analysis-of-intermediate-risk-prostate-cancer-patients-treated-on-nrg-oncology-rtog-9202
#1
Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, Herbert Lepor, David J Grignon, Christopher A Peters, Seth A Rosenthal, Kenneth Zeitzer, John S Radwan, Colleen Lawton, Matthew B Parliament, Robert S Reznik, Howard M Sandler
PURPOSE: NRG Oncology RTOG 9202 was a randomized trial testing long-term adjuvant androgen deprivation (LTAD) versus initial androgen deprivation only (STAD) with external beam radiation therapy (RT) in mostly high-risk and some intermediate-risk prostate cancer patients. RTOG 9408 found an overall survival (OS) advantage in patients with cT1b-T2b disease and prostate-specific antigen (PSA) <20 ng/mL, with benefit observed mostly among intermediate-risk patients. It was still unknown whether intermediate-risk patients would experience an additional survival benefit with LTAD; thus, we performed a secondary analysis to explore whether LTAD had any incremental benefit beyond STAD among the intermediate-risk subset of RTOG 9202...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27155934/high-risk-prostate-cancer-the-role-of-surgical-management
#2
REVIEW
Alessandro Morlacco, R Jeffrey Karnes
High-risk prostate cancer (HR Pca) is a highly heterogeneous disease from a biological and clinical standpoint, and it carries a significant chance of morbidity and mortality. Despite the impact of PSA screening, a significant number of men continue to present with high risk disease and need adequate management: clinical evidence shows that a considerable fraction on men with HR PCa can be actually cured with either uni- or multi-modality approaches. Surgical treatment, once considered unfeasible in this setting, is acquiring more and more diffusion in modern clinical practice...
June 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27823639/prostate-cancer-perspectives-after-chaarted-optimizing-treatment-sequence
#3
REVIEW
Sergio Vázquez Estévez, Urbano Anido Herranz, Ovidio Fernández Calvo, Francisco Javier Afonso Afonso, Lucía Santomé Couto, Martín Lázaro Quintela, Luis León Mateos, Sonia Maciá Escalante
Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes castration-resistant, were considered as standard. In the last years, new drugs (abiraterone, enzalutamide, Ra-223, Sipuleucel) have been developed for prostate cancer treatment with important advantages in safety and efficacy. Results from the recent Chaarted study, in patients that received docetaxel for the hormone sensitive disease, have contributed to change the initial treatment approach in metastatic prostate cancer, in order to adapt the best sequence for each patient...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26482453/prostate-dose-painting-radiotherapy-and-radiobiological-guided-optimisation-enhances-the-therapeutic-ratio
#4
J Uzan, A E Nahum, I Syndikus
AIMS: To describe the treatment of 11 patients with radiobiologically guided dose-painting radiotherapy and report on toxicity. MATERIALS AND METHODS: Boost volumes were identified with functional magnetic resonance imaging scans in 11 patients with high-risk prostate cancer. Patients were treated using a dose-painting approach; the boost dose was limited to 86 Gy in 37 fractions, while keeping the rectal normal tissue complication probability to 5-6%. Rotational intensity-modulated radiotherapy was used with daily image guidance and fiducial markers...
March 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27133945/should-treatment-with-radiation-and-androgen-deprivation-therapy-be-considered-the-gold-standard-for-men-with-unfavourable-intermediate-to-high-risk-and-locally-advanced-prostate-cancer
#5
EDITORIAL
M Roach
No abstract text is available yet for this article.
August 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27051534/pelvic-radiotherapy-versus-radical-prostatectomy-with-limited-lymph-node-sampling-for-high-grade-prostate-adenocarcinoma
#6
Christopher B Baker, Andrew M McDonald, Eddy S Yang, Rojymon Jacob, Soroush Rais-Bahrami, Jeffrey W Nix, John B Fiveash
Purpose. To compare oncologic outcomes for patients with Gleason score (GS) ≥ 8 prostate adenocarcinoma treated with radical prostatectomy (RP) versus external beam radiotherapy combined with androgen deprivation (RT + ADT). Methods. Between 2001 and 2014, 121 patients with GS ≥ 8 were treated at our institution via RT + ADT (n = 71) or RP (n = 50) with ≥ 1 year of biochemical follow-up. Endpoints included biochemical failure (BF), distant metastasis, and initiation of salvage ADT. Results. The RT + ADT group was older, had higher biopsy GS, and had greater risk of lymph node involvement...
2016: Prostate Cancer
https://www.readbyqxmd.com/read/27022486/prostate-radiotherapy-in-the-era-of-advanced-imaging-and-precision-medicine
#7
REVIEW
Caleb R Dulaney, Daniel O Osula, Eddy S Yang, Soroush Rais-Bahrami
Tremendous technological advancements in prostate radiotherapy have decreased treatment toxicity and improved clinical outcomes for men with prostate cancer. While these advances have allowed for significant treatment volume reduction and whole-organ dose escalation, further improvement in prostate radiotherapy has been limited by classic techniques for diagnosis and risk stratification. Developments in prostate imaging, image-guided targeted biopsy, next-generation gene expression profiling, and targeted molecular therapies now provide information to stratify patients and select treatments based on tumor biology...
2016: Prostate Cancer
https://www.readbyqxmd.com/read/27891254/prostate-cancer-epigenetic-alterations-risk-factors-and-therapy
#8
REVIEW
Mankgopo M Kgatle, Asgar A Kalla, Muhammed M Islam, Mike Sathekge, Razia Moorad
Prostate cancer (PCa) is the most prevalent urological cancer that affects aging men in South Africa, and mechanisms underlying prostate tumorigenesis remain elusive. Research advancements in the field of PCa and epigenetics have allowed for the identification of specific alterations that occur beyond genetics but are still critically important in the pathogenesis of tumorigenesis. Anomalous epigenetic changes associated with PCa include histone modifications, DNA methylation, and noncoding miRNA. These mechanisms regulate and silence hundreds of target genes including some which are key components of cellular signalling pathways that, when perturbed, promote tumorigenesis...
2016: Prostate Cancer
https://www.readbyqxmd.com/read/28049538/risk-of-second-cancer-following-radiotherapy-for-prostate-cancer-a-population-based-analysis
#9
Nina-Sophie Hegemann, Anne Schlesinger-Raab, Ute Ganswindt, Claudia Hörl, Stephanie E Combs, Dieter Hölzel, Jürgen E Gschwend, Christian Stief, Claus Belka, Jutta Engel
BACKGROUND: To investigate the risk of second cancer and radiation induced second cancer following prostate cancer radiotherapy. METHODS: We compared men with radiotherapy only with those treated with radical prostatectomy only and those with radiotherapy after radical prostatectomy. Cumulative incidences of second cancers were calculated. Cox analyses were performed to identify determinants influencing second cancer incidence. RESULTS: Nineteen thousand five hundred thirty eight patients were analyzed...
January 3, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28061904/classifying-high-risk-versus-very-high-risk-prostate-cancer-is-it-relevant-to-outcomes-of-conformal-radiotherapy-and-androgen-deprivation
#10
Akram Saad, Jeffrey Goldstein, Yaacov R Lawrence, Benjamin Spieler, Raya Leibowitz-Amit, Raanan Berger, Tima Davidson, Damien Urban, Lev Tsang, Dror Alezra, Ilana Weiss, Zvi Symon
OBJECTIVE: To evaluate outcomes in prostate cancer patients classified as high-risk (HR) or very high-risk (VHR) who were treated with conformal radiation therapy (CRT) and androgen deprivation therapy (ADT). METHODS: Between 11/2001 and 3/2012, 203 patients with HR disease received CRT to the prostate (78-82 Gy) and pelvic lymph nodes (46-50 Gy) with ADT (6 m-2 years). Median follow-up was 50 months (12 m-142 m). Biochemical failure was defined according to Phoenix definition...
January 6, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/27825433/advancement-of-mr-and-pet-mr-in-prostate-cancer
#11
REVIEW
Liza Lindenberg, Mark Ahlman, Baris Turkbey, Esther Mena, Peter Choyke
Multiparametric magnetic resonance (mpMRI) imaging has assumed a larger role in the diagnosis and management of prostate cancer. The current method of detecting prostate cancer relies on blind systematic biopsy, guided only by transrectal ultrasound that generally directs the needle biopsy to sextants of the prostate rather than specific lesions. MpMRI is playing an increasing role in the detection of primary cancer as it can visualize cancers and direct biopsies. However, even mpMRI is inherently nonspecific and numerous biopsies performed under MR guidance prove to be negative...
November 2016: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27838147/long-term-outcomes-of-a-phase-ii-trial-of-moderate-hypofractionated-image-guided-intensity-modulated-radiotherapy-ig-imrt-for-localized-prostate-cancer
#12
Hester Lieng, Melania Pintilie, Andrew Bayley, Alejandro Berlin, Robert Bristow, Peter Chung, Mary Gospodarowicz, Roger Huang, Cynthia Ménard, Padraig Warde, Charles Catton
PURPOSE: To evaluate long-term radiation toxicity and biochemical control of two moderately hypofractionated radiotherapy regimens for prostate cancer. MATERIAL AND METHODS: Eligible men with localized prostate cancer received image-guided intensity modulated radiotherapy (IG-IMRT) to a dose of 60 or 66Gy in 3Gy fractions in a phase II trial. Endpoints included late gastrointestinal (GI) and genitourinary (GU) toxicity and biochemical failure (FFBF). RESULTS: Ninety-six men received 60Gy and 27 received 66Gy...
January 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27802360/prostate-cancer-developing-novel-approaches-to-castration-sensitive-disease
#13
REVIEW
Edoardo Francini, Mary-Ellen Taplin
Although androgen-deprivation therapy (ADT) remains the mainstay of castration-sensitive prostate cancer (CSPC) therapy, the disease's heterogeneity and the limited duration of the response have chaperoned the introduction of chemotherapy and the investigation of novel hormonal targeted agents in this setting. Combinations of ADT plus chemotherapy or novel hormonal therapies are being tested at various stages of CSPC with promising results. Furthermore, immunotherapy and experimental drugs are also being actively investigated in this setting...
January 1, 2017: Cancer
https://www.readbyqxmd.com/read/27860163/11c-acetate-positron-emission-tomography-computed-tomography-imaging-for-detection-of-recurrent-disease-after-radical-prostatectomy-or-radiotherapy-in-patients-with-prostate-cancer
#14
Lukas Hendrik Esch, Melanie Fahlbusch, Peter Albers, Hubertus Hautzel, Volker Müller-Mattheis
OBJECTIVES: To evaluate, in a prospective study, the effectiveness of computed tomography (CT)-matched 11C-acetate (AC) positron-emission tomography (PET) in patients with prostate cancer (PCa) who had prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or radiotherapy (RT). PATIENTS AND METHODS: In 103 relapsing patients after RP (n = 97) or RT (n = 6) AC-PET images and CT scans were obtained. In patients with AC-PET-positive results with localized PCa recurrence, detected lesions were resected and histologically verified or, after local RT, followed-up by PSA testing...
November 8, 2016: BJU International
https://www.readbyqxmd.com/read/27843596/international-survey-of-androgen-deprivation-therapy-adt-for-non-metastatic-prostate-cancer-in-19-countries
#15
Alexander Liede, David C Hallett, Kirsty Hope, Alex Graham, Jorge Arellano, Vahakn B Shahinian
BACKGROUND: Continuous androgen deprivation therapy (CADT) is commonly used for patients with non-metastatic prostate cancer as primary therapy for high-risk disease, adjuvant therapy together with radiation or for recurrence after initial local therapy. Intermittent ADT (IADT), a recently developed alternative strategy for providing ADT, is thought to potentially reduce adverse effects, but little is known about practice patterns relating to it. We aimed to describe factors related to physicians' ADT use and modality for patients with non-metastatic prostate cancer...
2016: ESMO Open
https://www.readbyqxmd.com/read/27791181/targeted-molecular-genetic-imaging-and-ligand-directed-therapy-in-aggressive-variant-prostate-cancer
#16
Fortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, Sara D'Angelo, Andrey S Dobroff, Marc Barry, Lesley C Lomo, Fernanda I Staquicini, Marina Cardó-Vila, Suren Soghomonyan, Mian M Alauddin, Leo G Flores, Marco A Arap, Richard C Lauer, Paul Mathew, Eleni Efstathiou, Ana M Aparicio, Patricia Troncoso, Nora M Navone, Christopher J Logothetis, Serena Marchiò, Juri G Gelovani, Richard L Sidman, Renata Pasqualini, Wadih Arap
Aggressive variant prostate cancers (AVPC) are a clinically defined group of tumors of heterogeneous morphologies, characterized by poor patient survival and for which limited diagnostic and treatment options are currently available. We show that the cell surface 78-kDa glucose-regulated protein (GRP78), a receptor that binds to phage-display-selected ligands, such as the SNTRVAP motif, is a candidate target in AVPC. We report the presence and accessibility of this receptor in clinical specimens from index patients...
October 24, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27823821/prostate-high-dose-rate-brachytherapy-as-monotherapy-for-low-and-intermediate-risk-prostate-cancer-early-toxicity-and-quality-of-life-results-from-a-randomized-phase-ii-clinical-trial-of-one-fraction-of-19gy-or-two-fractions-of-13-5gy
#17
Gerard Morton, Hans T Chung, Merrylee McGuffin, Joelle Helou, Laura D'Alimonte, Ananth Ravi, Patrick Cheung, Ewa Szumacher, Stanley Liu, Motasem Al-Hanaqta, Liying Zhang, Alexandre Mamedov, Andrew Loblaw
BACKGROUND AND PURPOSE: Multi-fraction high dose-rate (HDR) brachytherapy as monotherapy is safe and effective for low and intermediate risk prostate cancer. Two or single fraction regimens have some radiobiological rationale. The purpose is to determine toxicity and effect on health related quality of life (HRQOL) of single fraction 19Gy or 13.5Gy×2. MATERIALS AND METHODS: Eligible patients had low or intermediate risk prostate cancer, prostate volume <60cc, and no androgen deprivation use...
January 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27752756/pet-imaging-for-lymph-node-dissection-in-prostate-cancer
#18
Elena Incerti, Paola Mapelli, Luigi Gianolli, Maria Picchio
The detection of neoplastic lymph nodal involvement in prostate cancer (PCa) patients has relevant therapeutic and prognostic significance, both in the clinical settings of primary staging and restaging. Lymph nodal dissection (LND) currently represents the gold standard for evaluating the presence of lymph nodal involvement. However, this procedure is invasive, associated with morbidity, and may fail in detecting all potential lymph nodal metastatic regions. Currently the criteria for lymph nodal detection using conventional imaging techniques mainly rely on morphological assessment with unsatisfactory diagnostic accuracy...
October 17, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27859018/the-role-of-adjuvant-radiotherapy-in-pathologically-lymph-node-positive-prostate-cancer
#19
Naresh Jegadeesh, Yuan Liu, Chao Zhang, Jim Zhong, Richard J Cassidy, Theresa Gillespie, Omer Kucuk, Peter Rossi, Viraj A Master, Mehrdad Alemozaffar, Ashesh B Jani
BACKGROUND: Postoperative management of prostate cancer with lymph node involvement (LNI) is controversial. Retrospective evidence supports the selective use of radiotherapy (RT) after extended pelvic lymph node dissection. It is unclear whether this is generalizable to practice in the United States, where extended dissection is uncommon. The authors identified patients with LNI who potentially could derive a survival benefit with adjuvant RT plus androgen-deprivation therapy (ADT). METHODS: Patients with N1M0 prostate adenocarcinoma who underwent radical prostatectomy (RP) and subsequently received ADT from 2003 through 2011 were identified from the National Cancer Database...
November 8, 2016: Cancer
https://www.readbyqxmd.com/read/27864015/prediction-of-overall-survival-for-patients-with-metastatic-castration-resistant-prostate-cancer-development-of-a-prognostic-model-through-a-crowdsourced-challenge-with-open-clinical-trial-data
#20
Justin Guinney, Tao Wang, Teemu D Laajala, Kimberly Kanigel Winner, J Christopher Bare, Elias Chaibub Neto, Suleiman A Khan, Gopal Peddinti, Antti Airola, Tapio Pahikkala, Tuomas Mirtti, Thomas Yu, Brian M Bot, Liji Shen, Kald Abdallah, Thea Norman, Stephen Friend, Gustavo Stolovitzky, Howard Soule, Christopher J Sweeney, Charles J Ryan, Howard I Scher, Oliver Sartor, Yang Xie, Tero Aittokallio, Fang Liz Zhou, James C Costello
BACKGROUND: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease...
January 2017: Lancet Oncology
label_collection
label_collection
7601
1
2
2016-12-01 03:22:11
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"